Instrument Inactif

Autres langues Palatin Technologies, Inc. Nyse

Actions

PTN

US6960773041

Cours en clôture Nyse Autres places de cotation
- ^USD	-

08/04	Palatin annonce les résultats de l'essai clinique de phase 3 Pl9643 Melody-1 sur la sécheresse oculaire présentés à l'American Society of Cataract and Refractive Surgery (Ascrs) 2024	CI
28/02	Mise à jour sectorielle : Les actions du secteur de la santé déclinent en fin d'après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity	03/05
Palatin to Host Virtual KOL Event 'Beyond GLPs, the Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance' on May 8, 2024	01/05
PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024	09/04
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	08/04
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	29/02
Sector Update: Health Care Stocks Decline Late Afternoon	28/02
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	28/02
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE	06/02
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease	05/02
PALATIN ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING	31/01
PALATIN PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC PRIORITIES FOR CALENDAR YEAR 2024	09/01
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024	08/01
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.	03/01
Cosette Pharmaceuticals, Inc. acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. for approximately $170 million.	20/12
Top Premarket Decliners	15/12
PALATIN REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE	15/11
Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
PALATIN TO REPORT FIRST QUARTER FISCAL YEAR 2024 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON NOVEMBER 14, 2023	10/11
PALATIN ANNOUNCES CLOSING OF $5 MILLION REGISTERED DIRECT OFFERING	25/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Palatin Technologies, Inc. Nyse

Actions

PTN

US6960773041

Autres langues

Filtres